Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Extracellular matrix proteins as diagnostic markers of breast carcinoma.

Giussani M, Landoni E, Merlino G, Turdo F, Veneroni S, Paolini B, Cappelletti V, Miceli R, Orlandi R, Triulzi T, Tagliabue E.

J Cell Physiol. 2018 Mar 9. doi: 10.1002/jcp.26513. [Epub ahead of print]

PMID:
29521413
2.

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.

Di Modica M, Tagliabue E, Triulzi T.

Dis Markers. 2017;2017:7849108. doi: 10.1155/2017/7849108. Epub 2017 Dec 18. Review.

3.

Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.

Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, Tuccitto A, Tagliabue E, Castelli C, Rivoltini L.

Semin Cancer Biol. 2017 Apr;43:74-89. doi: 10.1016/j.semcancer.2017.03.001. Epub 2017 Mar 6. Review.

4.

Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells.

Bianchi F, Sommariva M, De Cecco L, Triulzi T, Romero-Cordoba S, Tagliabue E, Sfondrini L, Balsari A.

Cell Cycle. 2016 Dec;15(23):3220-3229. Epub 2016 Oct 18.

5.

Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.

Di Modica M, Regondi V, Sandri M, Iorio MV, Zanetti A, Tagliabue E, Casalini P, Triulzi T.

Cancer Lett. 2017 Jan 1;384:94-100. doi: 10.1016/j.canlet.2016.09.013. Epub 2016 Sep 28.

6.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

7.

Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.

Triulzi T, Bianchi GV, Tagliabue E.

Future Oncol. 2016 Jun;12(11):1413-28. doi: 10.2217/fon-2015-0025. Epub 2016 Mar 23. Review.

PMID:
27007660
8.

Sulfurtransferase and thioredoxin specifically interact as demonstrated by bimolecular fluorescence complementation analysis and biochemical tests.

Henne M, König N, Triulzi T, Baroni S, Forlani F, Scheibe R, Papenbrock J.

FEBS Open Bio. 2015 Oct 8;5:832-43. doi: 10.1016/j.fob.2015.10.001. eCollection 2015.

9.

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.

Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E.

Oncotarget. 2016 Jan 5;7(1):255-65. doi: 10.18632/oncotarget.6353.

10.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

11.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

12.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

13.

Stromal responses among carcinomas--letter.

Triulzi T, Orlandi R, Tagliabue E.

Clin Cancer Res. 2014 Mar 1;20(5):1396. doi: 10.1158/1078-0432.CCR-13-3005. No abstract available.

14.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization.

Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P, Tagliabue E.

Int J Cancer. 2014 Jun 15;134(12):2789-97. doi: 10.1002/ijc.28608. Epub 2013 Nov 30.

15.

Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.

Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E.

PLoS One. 2013;8(2):e56761. doi: 10.1371/journal.pone.0056761. Epub 2013 Feb 18.

16.

FOXP3 expression in tumor cells and implications for cancer progression.

Triulzi T, Tagliabue E, Balsari A, Casalini P.

J Cell Physiol. 2013 Jan;228(1):30-5. doi: 10.1002/jcp.24125. Review.

PMID:
22674548
17.

Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM.

Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19.

18.

Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.

Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E.

Cell Oncol. 2010;32(5-6):361-72. doi: 10.3233/CLO-2010-0520.

19.

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O.

Mol Oncol. 2009 Dec;3(5-6):469-82. doi: 10.1016/j.molonc.2009.07.003. Epub 2009 Aug 4.

20.

microRNA-205 regulates HER3 in human breast cancer.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E.

Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10.

21.

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A.

J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2.

PMID:
19255331
22.

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL.

J Pathol. 2008 Feb;214(3):357-67.

PMID:
18044827
23.

Radiation effects on development of HER2-positive breast carcinomas.

Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Ménard S, Tagliabue E.

Clin Cancer Res. 2007 Jan 1;13(1):46-51.

Supplemental Content

Loading ...
Support Center